Loading...
Glibenclamide — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Glibenclamide
2025-Q4
Comprehensive analysis of India’s glibenclamide export trade — suppliers, buyers, prices, routes, and every shipment record.
89
Shipments
$253K
Trade Value
35
Suppliers
38
Buyers
31
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/glibenclamide
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s glibenclamide trade — 2025-Q4
KEY TAKEAWAY
Glibenclamide 2025-Q4 exports total $252.8K across 31 countries, with CIPLA LTD commanding 18.5% market share.
TOTAL SHIPMENTS
89
2025-Q4
EXPORT VALUE
$252.8K
FOB USD
TOTAL QUANTITY
4.9M
units shipped
INDIAN SUPPLIERS
35
unique exporters
GLOBAL BUYERS
38
unique importers
DESTINATIONS
31
countries
MEDIAN UNIT PRICE
$0.310
per unit
TOP-5 SHARE
65.2%
of total USD
BRANDED SHARE
59.6%
53 shipments
DOSAGE FORMS
1
product types
6 KEY FINDINGS
1
CIPLA LTD is India's #1 Glibenclamide exporter with $46.7K (18.5% market share).→ §5, Indian Supplier Rankings
2
Glibenclamide reached 31 countries, with Venezuela as the top destination ($61.7K).→ §4, Global Destination Map
3
Market concentration is low (HHI: 1089) — top 10 suppliers control 85.8% of exports.→ §5, Indian Supplier Rankings
4
94.7% of buyers (36 of 38) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (99.2%) across 1 dosage forms.→ §7, Price Benchmarks
6
31 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 CIPLA LTD leads in volume — how do 30 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian glibenclamide exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Glibenclamide report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial glibenclamide trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian glibenclamide suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Glibenclamide India trade report
Product scope
Glibenclamide
All variants merged — branded and generic formulations of glibenclamide
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
89
Every commercial glibenclamide trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a steady rise: Oct $38.1K, Nov $85.9K, Dec $128.8K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$38.1K
Oct USD
14 shipments
2
$85.9K
Nov USD
+125.2% MoM
3
$128.8K
Dec USD
+50.0% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 125.2% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $38K, making it the weakest month by value.
Fig 3.2 Q4 cumulative USD reached $253K.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $48K rise in Nov, $43K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $38K | 14 shipments |
| Nov | $86K | 27 shipments |
| Dec | $129K | 48 shipments |
| Q4 Total | $253K | 89 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: Venezuela held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: SAGA LIFESCIENCES LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import glibenclamide from India, how much they buy, and who supplies each market
KEY TAKEAWAY
Venezuela absorbs 24.4% of India’s 2025-Q4 glibenclamide trade ($61.7K). Beyond the top 10 destinations, 31 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 12 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 31 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much glibenclamide India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$19K
7.4% of trade
7 countries · 10 shipments
Europe
$15K
6.1% of trade
3 countries · 7 shipments
Americas
$101K
39.9% of trade
8 countries · 31 shipments
Africa
$118K
46.6% of trade
12 countries · 40 shipments
Oceania
$31
0.0% of trade
1 countries · 1 shipments
Fig 4.1 Venezuela is the #1 corridor ($62K) — 30 flow arcs from India radiate across 5 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian glibenclamide it receives (light = low, dark = high). Orange arcs radiate from India to the top 30 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Venezuela | $62K | 8 | LUCENT BIOTECH LTD | $45K | LARK LABORATORIES (INDIA) LTD | $11K | SAGA LIFESCIENCES LTD | $5K |
| 2 | Madagascar | $47K | 7 | CIPLA LTD | $47K | ACCRESHA LIFECARE PVT LTD | $739 | — | — |
| 3 | Tanzania | $32K | 7 | ZYDUS LIFESCIENCES LTD | $28K | SHALINA LABORATORIES PVT LTD | $4K | AGOG PHARMA LTD | $41 |
| 4 | DR Congo | $16K | 4 | SHALINA LABORATORIES PVT LTD | $14K | AURA LIFECARE PVT LTD | $2K | — | — |
| 5 | Dominican Republic | $14K | 5 | SAGA LIFESCIENCES LTD | $8K | WEXFORD LABORATORIES PVT LTD | $4K | CUMED LIFESCIENCES | $912 |
| 6 | Nicaragua | $13K | 2 | INTERMED LABORATORIES PVT LTD | $13K | — | — | — | — |
| 7 | Netherlands | $11K | 4 | MEDOPHARM | $11K | RUCHA ENTERPRISES | $3 | — | — |
| 8 | Israel | $9K | 1 | S KANT HEALTHCARE LTD | $9K | — | — | — | — |
| 9 | Kenya | $8K | 6 | ZYDUS LIFESCIENCES LTD | $6K | AGOG PHARMA LTD | $3K | SHALINA LABORATORIES PVT LTD | $5 |
| 10 | Guyana | $7K | 9 | MARYUS HEALTHCARE PVT LTD | $5K | AASHIRWAD PHARMA INTERNATIONAL PVT LTD | $2K | FENNY GLOBAL CARE PVT LTD | $141 |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 7.4% of USD — but Venezuela is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
24.4%
#1 country share
Venezuela alone
67.4%
Top 5 share
5 of 31 countries
94.0%
Top 15 share
Long tail of 16 countries = 6.0%
HHI 1267
Destination HHI
Competitive spread
31
Countries served
Global pharma reach from India
12
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
35 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
CIPLA LTD ($46.7K, 18.5% share) and LUCENT BIOTECH LTD ($45.4K) together control 36.4% of India’s 2025-Q4 glibenclamide trade. The top 5 suppliers hold 65.2%. 35 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian glibenclamide suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 CIPLA LTD leads by $1K over LUCENT BIOTECH LTD — top 20 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: AASHIRWAD PHARMA INTERNATIONAL is #20 by value but #7 by volume.
Fig 5.2 SHALINA LABORATORIES PVT LTD also leads by shipment count (14) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: AASHIRWAD PHARMA INTERNATIONAL moves from #7 by volume to #20 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 35 glibenclamide suppliers split into strategic segments
KEY TAKEAWAY
9 suppliers (25%) generate 83.5% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 CIPLA LTD and LUCENT BIOTECH LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 83.5% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | CIPLA LTD | 1 | 1 | $47K |
| 2 | LUCENT BIOTECH LTD | 1 | 1 | $45K |
| 3 | ZYDUS LIFESCIENCES LTD | 1 | 3 | $37K |
| 4 | SHALINA LABORATORIES PVT LTD | 1 | 5 | $20K |
| 5 | MEDOPHARM | 1 | 3 | $16K |
| 6 | SAGA LIFESCIENCES LTD | 1 | 2 | $14K |
| 7 | INTERMED LABORATORIES PVT LTD | 1 | 1 | $13K |
| 8 | LARK LABORATORIES (INDIA) LTD | 1 | 1 | $11K |
| 9 | S KANT HEALTHCARE LTD | 1 | 1 | $9K |
| 10 | MEDICAMEN BIOTECH LTD | 1 | 1 | $6K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the glibenclamide manufacturing hubs
KEY TAKEAWAY
Parel Mumbai Maharashtra and Roorkee together account for $92K of India’s 2025-Q4 glibenclamide trade.
Fig 5.5 Parel Mumbai Maharashtra (1 exporters, $47K) and Roorkee (1 exporters, $45K) are India’s glibenclamide capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
65.2%
Top 5 share
5 of 35 suppliers
85.8%
Top 10 share
10 of 35 suppliers
83.5%
Top 25% share
9 suppliers = 84% USD
HHI 1089
Supplier HHI
Competitive
35
Total suppliers
shipped Glibenclamide in 2025-Q4
20+ cities
Indian hubs
Parel Mumbai Maharashtra and Roorkee lead
§5.2 Coming next: 3 exporter deep-dive profiles
Each of the top 3 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | ZYDUS LIFESCIENCES LTD | $37K |
| #2 | SHALINA LABORATORIES PVT LTD | $20K |
| #3 | MEDOPHARM | $16K |
#3
EXPORTER PROFILE #1 OF 3
ZYDUS LIFESCIENCES LTD
Ponda · India’s #3 glibenclamide supplier by USD · 2025-Q4
2025-Q4 USD
$37K
14.6% market share
SHIPMENTS
8
avg $5K/ship
COUNTRIES
3
destination markets
BUYERS
4
3 single-sourced
BRANDED
88%
of shipments
DOSAGE FORMS
1
product types
TOP 3 DESTINATIONS
Tanzania is the #1 market at $28K (75% of trade), followed by Kenya at $6K. 3 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Tanzania | $28K | 3 | 74.6% |
| 2 | Kenya | $6K | 4 | 15.2% |
| 3 | Yemen | $4K | 1 | 10.2% |
MONTHLY TREND
Nov peaked at $37K. Oct was the weakest at $0.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 3/3 LOCKED IN
3 of 3 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| ABACUS PHARMA (A) LTD | Tanzania | $28K | ⚠ Locked |
| AL-JABAL DRUGS AND MED… | Yemen | $4K | ⚠ Locked |
| ABACUS PHARMA (AFRICA)… | Kenya | $3K | ⚠ Locked |
| Undisclosed buyer | Kenya | $3K | N/A |
#3
EXPORTER PROFILE #1 OF 3 — TRADE FLOW MAP
ZYDUS LIFESCIENCES LTD — Supplier → Country → Importer
3 destination countries, top 5 importers per country
Fig 5.P1.3 Tanzania absorbs $28K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 2 importers per destination.
#4
EXPORTER PROFILE #2 OF 3
SHALINA LABORATORIES PVT LTD
Mumbai · India’s #4 glibenclamide supplier by USD · 2025-Q4
2025-Q4 USD
$20K
7.9% market share
SHIPMENTS
14
avg $1K/ship
COUNTRIES
5
destination markets
BUYERS
4
3 single-sourced
BRANDED
86%
of shipments
DOSAGE FORMS
1
product types
TOP 5 DESTINATIONS
DR Congo is the #1 market at $14K (69% of trade), followed by Tanzania at $4K. 5 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | DR Congo | $14K | 3 | 69.0% |
| 2 | Tanzania | $4K | 3 | 20.5% |
| 3 | South Sudan | $2K | 5 | 10.5% |
| 4 | Angola | $8 | 2 | 0.0% |
| 5 | Kenya | $5 | 1 | 0.0% |
MONTHLY TREND
Nov peaked at $9K. Dec was the weakest at $4K.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 3/3 LOCKED IN
3 of 3 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| SHALINA HEALTHCARE SARL | DR Congo | $18K | ⚠ Locked |
| Undisclosed buyer | South Sudan | $1K | N/A |
| SHALINA PHARMACY LTD | South Sudan | $720 | ⚠ Locked |
| AFRICA PHARMACY LIMITADA | Angola | $8 | ⚠ Locked |
#4
EXPORTER PROFILE #2 OF 3 — TRADE FLOW MAP
SHALINA LABORATORIES PVT LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P2.3 DR Congo absorbs $14K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
#5
2025-Q4 USD
$16K
6.2% market share
SHIPMENTS
5
avg $3K/ship
COUNTRIES
3
destination markets
BUYERS
4
3 single-sourced
BRANDED
0%
of shipments
DOSAGE FORMS
1
product types
TOP 3 DESTINATIONS
Netherlands is the #1 market at $11K (69% of trade), followed by United Arab Emirates at $4K. 3 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | Netherlands | $11K | 2 | 68.6% |
| 2 | United Arab Emirates | $4K | 2 | 22.9% |
| 3 | Lebanon | $1K | 1 | 8.6% |
MONTHLY TREND
Nov peaked at $14K. Dec was the weakest at $0.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 3/3 LOCKED IN
3 of 3 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| Undisclosed buyer | United Arab Emirates | $7K | N/A |
| IMRES B.V | Netherlands | $5K | ⚠ Locked |
| IMPERIAL MEDICAL SOLUT… | United Arab Emirates | $2K | ⚠ Locked |
| U.N.R.W.A | Lebanon | $1K | ⚠ Locked |
#5
EXPORTER PROFILE #3 OF 3 — TRADE FLOW MAP
MEDOPHARM — Supplier → Country → Importer
3 destination countries, top 5 importers per country
Fig 5.P3.3 Netherlands absorbs $11K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 3 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
38 importers across 31 countries — who is buying Indian glibenclamide and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 25 importers together hold only 65.3% of total USD. 95% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian glibenclamide. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 LABOREX is the #1 importer at $39K (15.3%) — top 25 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 25 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
95%
Single-source
36 buyers rely on exactly 1 Indian supplier
0%
Dual-source
0 buyers use 2 Indian suppliers
3%
Multi-source (3–4)
1 buyers diversified across 3–4
3%
Broad-source (5+)
1 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source glibenclamide from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
Madagascar 3 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| LABOREX | CIPLA LTD | $39K | $0.028 | Tablet |
| OPHAM | CIPLA LTD | $8K | $0.027 | Tablet |
| SALAMA(CENTRAL PURCHAS… | ACCRESHA LIFECARE PV… | $738.599 | $0.424 | Tablet |
Guyana 3 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| NEW GPC INC | MARYUS HEALTHCARE PV… | $5K | $3.590 | Tablet |
| POONAI BHIGROOG | AASHIRWAD PHARMA INT… | $45.869 | $0.229 | Tablet |
| DR BALWANT SINGHS HOSP… | SOINS IMPEX | $19.212 | $1.130 | Tablet |
Tanzania 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| ABACUS PHARMA (A) LTD | ZYDUS LIFESCIENCES LTD | $28K | $0.454 | Tablet |
| SUN ENTERPRISES LTD | AGOG PHARMA LTD | $41.002 | $0.0041 | Tablet |
DR Congo 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| SHALINA HEALTHCARE SARL | SHALINA LABORATORIES… | $18K | $0.113 | Tablet |
| NEW CESAMEX SARL | AURA LIFECARE PVT LTD | $2K | $0.293 | Tablet |
Dominican Republic 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| LABOPHARMACOS SRL | WEXFORD LABORATORIES… | $4K | $0.022 | Tablet |
| BERYL PHARMA SRL | CUMED LIFESCIENCES | $912.471 | $0.344 | Tablet |
§6.3 Price positioning — top 25 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | LABOREX | Madagascar | $39K | $10K | Budget |
| 2 | ABACUS PHARMA (A) LTD | Tanzania | $28K | $9K | Budget |
| 3 | SHALINA HEALTHCARE S… | DR Congo | $18K | $3K | Budget |
| 4 | UNIVERSAL MARKETING … | Nicaragua | $13K | $7K | Budget |
| 5 | LABORATORIOS BUKA C.A | Venezuela | $11K | $11K | Budget |
| 6 | OPHAM | Madagascar | $8K | $4K | Budget |
| 7 | PLANET PHARMACEUTICA… | Zimbabwe | $6K | $6K | Budget |
| 8 | IMRES B.V | Netherlands | $5K | $5K | Budget |
| 9 | NEW GPC INC | Guyana | $5K | $5K | Budget |
| 10 | LABOPHARMACOS SRL | Dominican Republic | $4K | $2K | Budget |
| 11 | AL-JABAL DRUGS AND M… | Yemen | $4K | $4K | Budget |
| 12 | ABACUS PHARMA (AFRIC… | Kenya | $3K | $964.000 | Budget |
| 13 | BALAXI HEALTHCARE GU… | Guatemala | $3K | $1K | Budget |
| 14 | GITTOES PHARMACEUTIC… | Kenya | $3K | $3K | Budget |
| 15 | PHARMACEUTICAL WAREH… | Netherlands Antilles | $2K | $1K | Budget |
| 16 | LUA COMERCIO GERAL L… | Angola | $2K | $2K | Budget |
| 17 | MSF SUPPLY | Belgium | $2K | $2K | Budget |
| 18 | NEW CESAMEX SARL | DR Congo | $2K | $2K | Budget |
| 19 | IMPERIAL MEDICAL SOL… | United Arab Emirates | $2K | $2K | Budget |
| 20 | U.N.R.W.A | Lebanon | $1K | $1K | Budget |
| 21 | DUSTI PHARMA LLC | Tajikistan | $1K | $1K | Budget |
| 22 | BERYL PHARMA SRL | Dominican Republic | $912.471 | $912.000 | Budget |
| 23 | SALAMA(CENTRAL PURCH… | Madagascar | $738.599 | $739.000 | Budget |
| 24 | SHALINA PHARMACY LTD | South Sudan | $720.292 | $240.000 | Budget |
| 25 | PHARMAVET LTD | Malawi | $546.531 | $547.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 20 × 20 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 CIPLA LTD → LABOREX is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian glibenclamide prices vary by supplier, country and dosage form
KEY TAKEAWAY
Glibenclamide prices span 53194× ($0.0008 → $42.41). The coefficient of variation is 3.51. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0008 | Lowest observed unit price |
| P5 | $0.0014 | 5th percentile |
| P25 | $0.028 | 25th percentile (Q1) |
| Median | $0.310 | 50th percentile (Q2) |
| P75 | $0.648 | 75th percentile (Q3) |
| P95 | $3.52 | 95th percentile |
| Max | $42.41 | Highest observed unit price |
| Mean | $1.88 | Arithmetic average |
| CV | 351% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 SYNCOM FORMULATIONS (INDIA) LTD prices at $35.34/unit vs market median $0.310.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. CIPLA LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. MEDOPHARM Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. CIRON DRUGS AND Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. LARK LABORATORIES (INDIA) Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Oct 2025 | SYNCOM FORMULATI… | Haiti | Tablet | 57 | $2K | $42.41 | Specialty / small-batch |
| Oct 2025 | SYNCOM FORMULATI… | Haiti | Tablet | 1 | $33.93 | $33.93 | Specialty / small-batch |
| Oct 2025 | SYNCOM FORMULATI… | Haiti | Tablet | 1 | $29.69 | $29.69 | Specialty / small-batch |
| Nov 2025 | REGAL LABORATORIES | Equatorial Guinea | Tablet | 11 | $152.14 | $14.11 | Specialty / small-batch |
| Dec 2025 | MARYUS HEALTHCAR… | Guyana | Tablet | 1K | $5K | $3.59 | Specialty / small-batch |
| Oct 2025 | MEDOPHARM | Lebanon | Tablet | 400 | $1K | $3.37 | Specialty / small-batch |
| Nov 2025 | MEDICAMEN BIOTEC… | Zimbabwe | Tablet | 2K | $6K | $2.83 | Specialty / small-batch |
| Nov 2025 | MEDOPHARM | United Arab Emirates | Tablet | 1K | $2K | $1.80 | Specialty / small-batch |
| Nov 2025 | MEDOPHARM | United Arab Emirates | Tablet | 1K | $2K | $1.80 | Specialty / small-batch |
| Nov 2025 | MEDOPHARM | Netherlands | Tablet | 3K | $5K | $1.80 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | SHALINA LABORATO… | Kenya | Tablet | 4K | $4.88 | $0.0014 | Bulk generic tablet |
| Dec 2025 | SHALINA LABORATO… | Tanzania | Tablet | 7K | $9.76 | $0.0014 | Bulk generic tablet |
| Dec 2025 | SHALINA LABORATO… | Tanzania | Tablet | 8K | $10.91 | $0.0014 | Bulk generic tablet |
| Dec 2025 | SHALINA LABORATO… | Angola | Tablet | 3K | $7.55 | $0.0023 | Bulk generic tablet |
| Oct 2025 | CADILA PHARMACEU… | Belgium | Tablet | 642K | $2K | $0.0034 | Bulk generic tablet |
| Oct 2025 | CIRON DRUGS AND … | Ghana | Tablet | 1.0M | $3K | $0.0035 | Bulk generic tablet |
| Dec 2025 | INTERMED LABORAT… | Nicaragua | Tablet | 140K | $534.34 | $0.0038 | Bulk generic tablet |
| Dec 2025 | AGOG PHARMA LTD | Tanzania | Tablet | 10K | $41.00 | $0.0041 | Bulk generic tablet |
| Nov 2025 | ZYDUS LIFESCIENC… | Yemen | Tablet | 639K | $4K | $0.0059 | Bulk generic tablet |
| Dec 2025 | ZYDUS LIFESCIENC… | Kenya | Tablet | 24K | $150.19 | $0.0063 | Bulk generic tablet |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship glibenclamide, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Glibenclamide leaves India through 14+ ports. The top 5 (NHAVA SHEVA SEA (JNPT), CHENNAI SEA, AHMEDABAD ICD) handle 91.4% of total USD. SEA moves 64% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 NHAVA SHEVA SEA (JNPT) handles $171K — top 14 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 Toamasina is the #1 global destination port — top 25 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
SEA dominates at 64% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
SEA
$209K
82.7% of USD · 64.0% of ships
ICD
$31K
12.1% of USD · 14.6% of ships
AIR
$13K
5.2% of USD · 21.3% of ships
Fig 8.3 The dominant corridor is NHAVA SHEVA SEA (JNPT) → Sea → Africa ($107K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
South Sudan is the most concentrated destination (HHI 10000, 1 suppliers). Dominican Republic is the most competitive (HHI 4848).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 South Sudan (HHI 10,000) is the most concentrated — Dominican Republic (HHI 4,848) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| LABOREX | Madagascar | CIPLA LTD | $39K | 4 | MEDIUM |
| ABACUS PHARMA (A) LTD | Tanzania | ZYDUS LIFESCIENC… | $28K | 3 | MEDIUM |
| SHALINA HEALTHCARE S… | DR Congo | SHALINA LABORATO… | $18K | 6 | MEDIUM |
| UNIVERSAL MARKETING … | Nicaragua | INTERMED LABORAT… | $13K | 2 | MEDIUM |
| LABORATORIOS BUKA C.A | Venezuela | LARK LABORATORIE… | $11K | 1 | MEDIUM |
| OPHAM | Madagascar | CIPLA LTD | $8K | 2 | MEDIUM |
| PLANET PHARMACEUTICA… | Zimbabwe | MEDICAMEN BIOTEC… | $6K | 1 | MEDIUM |
| IMRES B.V | Netherlands | MEDOPHARM | $5K | 1 | MEDIUM |
Conclusion: 36 buyers depend on exactly one Indian supplier, representing $166K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| Venezuela | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Madagascar | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Tanzania | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| DR Congo | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Dominican Republic | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Nicaragua | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Israel | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Kenya | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Guyana | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Zimbabwe | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Yemen | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Ghana | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Guatemala | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 13 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in Madagascar | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit South Sudan lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Guyana (5 suppliers) | This Q | HIGH |
| A6 | Enter Venezuela (3 suppliers) | This Q | MED |
| A8 | Build Madagascar distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (SAGA LIFESCIENCES) | This Q | MED |
| A7 | Register for Venezuela tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Guyana | Other | 5 | $7K | +26270.6% | LOW | Growing 26271% with only 5 competitors |
| 2 | Venezuela | Other | 3 | $62K | +296.3% | LOW | Growing 296% with only 3 competitors |
| 3 | Madagascar | Africa | 2 | $47K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Tanzania | Africa | 3 | $32K | 0% | LOW | Low competition (3 suppliers), accessible market |
| 5 | DR Congo | Africa | 2 | $16K | -4.9% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Dominican Republic | Other | 3 | $14K | 0% | LOW | Low competition (3 suppliers), accessible market |
| 7 | Nicaragua | Other | 1 | $13K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Netherlands | Other | 2 | $11K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Israel | Other | 1 | $9K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Kenya | Africa | 3 | $8K | 0% | LOW | Low competition (3 suppliers), accessible market |
| 11 | Zimbabwe | Africa | 1 | $6K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Yemen | Other | 1 | $4K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | United Arab Emirates | Other | 2 | $4K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Ghana | Africa | 1 | $3K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Guatemala | Other | 1 | $3K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 89 2025-Q4 Glibenclamide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/glibenclamide
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 89 2025-Q4 glibenclamide shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian glibenclamide shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
89
across all regions
TOTAL USD
$253K
2025-Q4 FOB value
UNITS
4.9M
tablets, capsules, etc.
SUPPLIERS
35
Indian exporters
BUYERS
38
global importers
COUNTRIES
31
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $118K (46.6%), spanning 12 countries.
35 Indian suppliers shipped to 38 buyers across 31 countries — average shipment value $3K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
12 countries · 40 shipments · $118K · 12 Indian suppliers · 19 buyers
SHIPMENTS
40
USD
$118K
COUNTRIES
12
SUPPLIERS
12
BUYERS
19
HHI
2,704
concentrated
Top 12 destination countries in Africa
1
Madagascar (40.2%)
$47K
2
Tanzania (26.9%)
$32K
3
DR Congo (13.6%)
$16K
4
Kenya (7.1%)
$8K
5
Zimbabwe (4.8%)
$6K
6
Ghana (2.9%)
$3K
7
Angola (2.0%)
$2K
8
South Sudan (1.8%)
$2K
9
Malawi (0.5%)
$546.53
10
Equatorial Guinea (0.1%)
$152.14
11
Somalia (0.1%)
$106.91
12
Seychelles (0.0%)
$15.85
Top 12 Indian suppliers into Africa
1
CIPLA LTD
$47K
2
ZYDUS LIFESCIENCES LTD
$33K
3
SHALINA LABORATORIES PVT LTD
$20K
4
MEDICAMEN BIOTECH LTD
$6K
5
AURA LIFECARE PVT LTD
$5K
6
CIRON DRUGS AND PHARMACEUTICALS PVT LTD
$3K
7
AGOG PHARMA LTD
$3K
8
ACCRESHA LIFECARE PVT LTD
$738.60
9
LEBEN LABORATORIES PVT LTD
$546.53
10
REGAL LABORATORIES
$152.14
11
CURE EARTH PHARMA
$106.91
12
NALIINI.R.EXPORT PVT LTD
$15.85
Top 17 Africa importers
1
LABOREX · Madagascar
$39K
2
ABACUS PHARMA (A) LTD · Tanzania
$28K
3
SHALINA HEALTHCARE SARL · DR Congo
$18K
4
OPHAM · Madagascar
$8K
5
PLANET PHARMACEUTICALS CHEMICALS · Zimbabwe
$6K
6
ABACUS PHARMA (AFRICA) LTD · Kenya
$3K
7
GITTOES PHARMACEUTICALS LTD · Kenya
$3K
8
LUA COMERCIO GERAL LIMITADA · Angola
$2K
9
NEW CESAMEX SARL · DR Congo
$2K
10
SALAMA(CENTRAL PURCHASING AGENCY · Madagascar
$738.60
11
SHALINA PHARMACY LTD · South Sudan
$720.29
12
PHARMAVET LTD · Malawi
$546.53
13
SONIA PHARMACY · Equatorial Guinea
$152.14
14
KALKAAL HOSPITAL · Somalia
$106.91
15
SUN ENTERPRISES LTD · Tanzania
$41.00
16
CENTRAL POINT PHARMACY · Seychelles
$15.85
17
AFRICA PHARMACY LIMITADA · Angola
$7.55
Top 1 dosage forms
1
Tablet
$118K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 4 | $11K | $3K |
| Nov | 15 | $56K | $4K |
| Dec | 21 | $51K | $2K |
Shipment register · 40 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — CIPLA LTD · 6 shipments · $47K | |||||||||||
| 1 | Nov 2025 | OPHAM | Madagascar | Tablet | 147.0K | NOS | $0.027 | $4K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| 2 | Nov 2025 | OPHAM | Madagascar | Tablet | 147.0K | NOS | $0.027 | $4K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| 3 | Dec 2025 | LABOREX | Madagascar | Tablet | 462.0K | NOS | $0.028 | $13K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| 4 | Dec 2025 | LABOREX | Madagascar | Tablet | 231.0K | NOS | $0.028 | $6K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| 5 | Dec 2025 | LABOREX | Madagascar | Tablet | 462.0K | NOS | $0.028 | $13K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| 6 | Dec 2025 | LABOREX | Madagascar | Tablet | 231.0K | NOS | $0.028 | $6K | NHAVA SHEVA SEA (JNPT) | Toamasina | SEA |
| SUPPLIER #2 — ZYDUS LIFESCIENCES LTD · 7 shipments · $33K | |||||||||||
| 7 | Nov 2025 | ABACUS PHARMA (AFRICA) LTD | Kenya | Tablet | 5.0K | NOS | $0.549 | $3K | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 8 | Nov 2025 | UNKNOWN BUYER | Kenya | Tablet | 5.0K | NOS | $0.549 | $3K | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 9 | Nov 2025 | ABACUS PHARMA (A) LTD | Tanzania | Tablet | 23.0K | NOS | $0.599 | $14K | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 10 | Nov 2025 | ABACUS PHARMA (A) LTD | Tanzania | Tablet | 23.0K | NOS | $0.599 | $14K | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 11 | Dec 2025 | ABACUS PHARMA (AFRICA) LTD | Kenya | Tablet | 24.0K | NOS | $0.0063 | $150.19 | NHAVA SHEVA SEA (JNPT) | Mombasa | AIR |
| 12 | Dec 2025 | ABACUS PHARMA (A) LTD | Tanzania | Tablet | 15.0K | NOS | $0.0068 | $102.37 | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 13 | Dec 2025 | ABACUS PHARMA (AFRICA) LTD | Kenya | Tablet | 2.4K | NOS | $0.0063 | $14.88 | NHAVA SHEVA SEA (JNPT) | Mombasa | AIR |
| SUPPLIER #3 — SHALINA LABORATORIES PVT LTD · 14 shipments · $20K | |||||||||||
| 14 | Oct 2025 | SHALINA HEALTHCARE SARL | DR Congo | Tablet | 52.7K | NOS | $0.129 | $7K | NHAVA SHEVA SEA (JNPT) | Kinshasa | SEA |
| 15 | Nov 2025 | SHALINA HEALTHCARE SARL | Tanzania | Tablet | 32.0K | NOS | $0.127 | $4K | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 16 | Nov 2025 | SHALINA PHARMACY LTD | South Sudan | Tablet | 3.6K | NOS | $0.128 | $459.90 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 17 | Nov 2025 | SHALINA PHARMACY LTD | South Sudan | Tablet | 2.0K | NOS | $0.128 | $255.52 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 18 | Nov 2025 | UNKNOWN BUYER | South Sudan | Tablet | 3.6K | NOS | $0.128 | $459.90 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 19 | Nov 2025 | UNKNOWN BUYER | South Sudan | Tablet | 3.6K | NOS | $0.128 | $459.90 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 20 | Nov 2025 | UNKNOWN BUYER | South Sudan | Tablet | 3.6K | NOS | $0.128 | $459.90 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 21 | Nov 2025 | SHALINA HEALTHCARE SARL | DR Congo | Tablet | 22.8K | PCS | $0.119 | $3K | NHAVA SHEVA SEA (JNPT) | Matadi | SEA |
| 22 | Dec 2025 | SHALINA HEALTHCARE SARL | DR Congo | Tablet | 35.2K | PCS | $0.122 | $4K | NHAVA SHEVA SEA (JNPT) | Matadi | SEA |
| 23 | Dec 2025 | AFRICA PHARMACY LIMITADA | Angola | Tablet | 3.2K | PCS | $0.0000 | $0.0000 | NHAVA SHEVA SEA (JNPT) | Luanda | SEA |
| 24 | Dec 2025 | AFRICA PHARMACY LIMITADA | Angola | Tablet | 3.2K | PCS | $0.0023 | $7.55 | NHAVA SHEVA SEA (JNPT) | Luanda | SEA |
| 25 | Dec 2025 | SHALINA HEALTHCARE SARL | Tanzania | Tablet | 8.0K | NOS | $0.0014 | $10.91 | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 26 | Dec 2025 | SHALINA HEALTHCARE SARL | Tanzania | Tablet | 7.2K | NOS | $0.0014 | $9.76 | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| 27 | Dec 2025 | SHALINA PHARMACY LTD | Kenya | Tablet | 3.6K | PCS | $0.0014 | $4.88 | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| SUPPLIER #4 — MEDICAMEN BIOTECH LTD · 1 shipments · $6K | |||||||||||
| 28 | Nov 2025 | PLANET PHARMACEUTICALS CHEMICALS | Zimbabwe | Tablet | 2.0K | NOS | $2.83 | $6K | DELHI AIR | HARARE | AIR |
| SUPPLIER #5 — AURA LIFECARE PVT LTD · 2 shipments · $5K | |||||||||||
| 29 | Dec 2025 | LUA COMERCIO GERAL LIMITADA | Angola | Tablet | 9.6K | NOS | $0.244 | $2K | MUNDRA SEA | Luanda | SEA |
| 30 | Dec 2025 | NEW CESAMEX SARL | DR Congo | Tablet | 7.4K | NOS | $0.293 | $2K | MUNDRA SEA | Matadi | SEA |
| SUPPLIER #6 — CIRON DRUGS AND PHARMACEUTICALS PVT LTD · 1 shipments · $3K | |||||||||||
| 31 | Oct 2025 | UNLISTED BUYER | Ghana | Tablet | 1.0M | NOS | $0.0035 | $3K | NHAVA SHEVA SEA (JNPT) | Tema | SEA |
| SUPPLIER #7 — AGOG PHARMA LTD · 2 shipments · $3K | |||||||||||
| 32 | Dec 2025 | GITTOES PHARMACEUTICALS LTD | Kenya | Tablet | 9.8K | NOS | $0.276 | $3K | NHAVA SHEVA SEA (JNPT) | Mombasa | SEA |
| 33 | Dec 2025 | SUN ENTERPRISES LTD | Tanzania | Tablet | 10.0K | NOS | $0.0041 | $41.00 | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| SUPPLIER #8 — ACCRESHA LIFECARE PVT LTD · 1 shipments · $738.60 | |||||||||||
| 34 | Dec 2025 | SALAMA(CENTRAL PURCHASING AGENCY | Madagascar | Tablet | 1.7K | NOS | $0.424 | $738.60 | AHMEDABAD ICD | TOAMASINA | ICD |
| SUPPLIER #9 — LEBEN LABORATORIES PVT LTD · 1 shipments · $546.53 | |||||||||||
| 35 | Oct 2025 | PHARMAVET LTD | Malawi | Tablet | 2.6K | NOS | $0.213 | $546.53 | NHAVA SHEVA SEA (JNPT) | Blantyre | SEA |
| SUPPLIER #10 — REGAL LABORATORIES · 1 shipments · $152.14 | |||||||||||
| 36 | Nov 2025 | SONIA PHARMACY | Equatorial Guinea | Tablet | 11 | KGS | $14.11 | $152.14 | CHAWAPAYAL ICD | MALABO | ICD |
| SUPPLIER #11 — CURE EARTH PHARMA · 3 shipments · $106.91 | |||||||||||
| 37 | Dec 2025 | KALKAAL HOSPITAL | Somalia | Tablet | 300 | NOS | $0.330 | $99.00 | CHENNAI AIR | MOGADISCHU | AIR |
| 38 | Dec 2025 | KALKAAL HOSPITAL | Somalia | Tablet | 60 | NOS | $0.130 | $7.80 | CHENNAI AIR | MOGADISCHU | AIR |
| 39 | Dec 2025 | KALKAAL HOSPITAL | Somalia | Tablet | 120 | NOS | $0.0009 | $0.109 | CHENNAI AIR | MOGADISCHU | AIR |
| SUPPLIER #12 — NALIINI.R.EXPORT PVT LTD · 1 shipments · $15.85 | |||||||||||
| 40 | Oct 2025 | CENTRAL POINT PHARMACY | Seychelles | Tablet | 25 | NOS | $0.634 | $15.85 | CHENNAI AIR | MAHE ISLAND | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
7 countries · 10 shipments · $19K · 7 Indian suppliers · 8 buyers
SHIPMENTS
10
USD
$19K
COUNTRIES
7
SUPPLIERS
7
BUYERS
8
HHI
3,212
concentrated
Top 7 destination countries in Asia
1
Israel (45.4%)
$9K
2
Yemen (20.1%)
$4K
3
United Arab Emirates (19.2%)
$4K
4
Lebanon (7.2%)
$1K
5
Tajikistan (6.8%)
$1K
6
Vietnam (1.2%)
$233.07
7
Singapore (0.0%)
$0.013
Top 7 Indian suppliers into Asia
1
S KANT HEALTHCARE LTD
$9K
2
MEDOPHARM
$5K
3
ZYDUS LIFESCIENCES LTD
$4K
4
SPEY MEDICAL PVT LTD
$1K
5
MICRO LABS LTD
$233.07
6
MOVID IMPEX
$2.72
7
RUCHA ENTERPRISES
$0.013
Top 6 Asia importers
1
AL-JABAL DRUGS AND MEDICAL APPLIANC · Yemen
$4K
2
IMPERIAL MEDICAL SOLUTIONS FZE · United Arab Emirates
$2K
3
U.N.R.W.A · Lebanon
$1K
4
DUSTI PHARMA LLC · Tajikistan
$1K
5
CENTRAL PHARMACEUTICAL JOINT STOCK · Vietnam
$233.07
6
EMIRATES POST GROUP · United Arab Emirates
$2.72
Top 1 dosage forms
1
Tablet
$19K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $11K | $4K |
| Nov | 3 | $7K | $2K |
| Dec | 4 | $235.81 | $58.95 |
Shipment register · 10 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — S KANT HEALTHCARE LTD · 1 shipments · $9K | |||||||||||
| 1 | Oct 2025 | UNLISTED BUYER | Israel | Tablet | 24.0K | NOS | $0.355 | $9K | NHAVA SHEVA SEA (JNPT) | Ashdod | SEA |
| SUPPLIER #2 — MEDOPHARM · 3 shipments · $5K | |||||||||||
| 2 | Oct 2025 | U.N.R.W.A | Lebanon | Tablet | 400 | NOS | $3.37 | $1K | ENNORE SEA | Beirut | SEA |
| 3 | Nov 2025 | IMPERIAL MEDICAL SOLUTIONS FZE | United Arab Emirates | Tablet | 1.0K | NOS | $1.80 | $2K | CHENNAI SEA | Jebel Ali | SEA |
| 4 | Nov 2025 | UNKNOWN BUYER | United Arab Emirates | Tablet | 1.0K | NOS | $1.80 | $2K | CHENNAI SEA | Jebel Ali | SEA |
| SUPPLIER #3 — ZYDUS LIFESCIENCES LTD · 1 shipments · $4K | |||||||||||
| 5 | Nov 2025 | AL-JABAL DRUGS AND MEDICAL APPLIANC | Yemen | Tablet | 638.9K | NOS | $0.0059 | $4K | NHAVA SHEVA SEA (JNPT) | Aden | SEA |
| SUPPLIER #4 — SPEY MEDICAL PVT LTD · 1 shipments · $1K | |||||||||||
| 6 | Oct 2025 | DUSTI PHARMA LLC | Tajikistan | Tablet | 4.9K | NOS | $0.262 | $1K | NHAVA SHEVA SEA (JNPT) | Dushanbe | SEA |
| SUPPLIER #5 — MICRO LABS LTD · 1 shipments · $233.07 | |||||||||||
| 7 | Dec 2025 | CENTRAL PHARMACEUTICAL JOINT STOCK | Vietnam | Tablet | 18.7K | PCS | $0.012 | $233.07 | BANGALORE AIR | HO CHI MINH C | SEA |
| SUPPLIER #6 — MOVID IMPEX · 2 shipments · $2.72 | |||||||||||
| 8 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 9 | NOS | $0.074 | $0.664 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 9 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 3 | NOS | $0.685 | $2.05 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| SUPPLIER #7 — RUCHA ENTERPRISES · 1 shipments · $0.013 | |||||||||||
| 10 | Dec 2025 | UNLISTED BUYER | Singapore | Tablet | 1 | NOS | $0.013 | $0.013 | MUMBAI AIR (SAHAR) | SINGAPORE | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
3 countries · 7 shipments · $15K · 4 Indian suppliers · 5 buyers
SHIPMENTS
7
USD
$15K
COUNTRIES
3
SUPPLIERS
4
BUYERS
5
HHI
5,364
concentrated
Top 3 destination countries in Europe
1
Netherlands (70.1%)
$11K
2
Netherlands Antilles (15.6%)
$2K
3
Belgium (14.2%)
$2K
Top 4 Indian suppliers into Europe
1
MEDOPHARM
$11K
2
YUYU MEDIMPEX PVT LTD
$2K
3
CADILA PHARMACEUTICALS LTD
$2K
4
RUCHA ENTERPRISES
$2.81
Top 3 Europe importers
1
IMRES B.V · Netherlands
$5K
2
PHARMACEUTICAL WAREHOUSING INC · Netherlands Antilles
$2K
3
MSF SUPPLY · Belgium
$2K
Top 1 dosage forms
1
Tablet
$15K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $2K | $2K |
| Nov | 3 | $11K | $4K |
| Dec | 3 | $2K | $802.12 |
Shipment register · 7 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MEDOPHARM · 2 shipments · $11K | |||||||||||
| 1 | Nov 2025 | IMRES B.V | Netherlands | Tablet | 3.0K | NOS | $1.80 | $5K | KAMARAJAR PORT SEA | Rotterdam | SEA |
| 2 | Nov 2025 | UNKNOWN BUYER | Netherlands | Tablet | 3.0K | NOS | $1.80 | $5K | KAMARAJAR PORT SEA | Rotterdam | SEA |
| SUPPLIER #2 — YUYU MEDIMPEX PVT LTD · 2 shipments · $2K | |||||||||||
| 3 | Dec 2025 | PHARMACEUTICAL WAREHOUSING INC | Netherlands Antilles | Tablet | 502 | NOS | $1.60 | $803.20 | AHMEDABAD ICD | WILLEMSTAD | ICD |
| 4 | Dec 2025 | PHARMACEUTICAL WAREHOUSING INC | Netherlands Antilles | Tablet | 1.0K | NOS | $1.60 | $2K | AHMEDABAD ICD | WILLEMSTAD | ICD |
| SUPPLIER #3 — CADILA PHARMACEUTICALS LTD · 1 shipments · $2K | |||||||||||
| 5 | Oct 2025 | MSF SUPPLY | Belgium | Tablet | 642.0K | TBS | $0.0034 | $2K | AHMEDABAD AIR | BRUSSELS | AIR |
| SUPPLIER #4 — RUCHA ENTERPRISES · 2 shipments · $2.81 | |||||||||||
| 6 | Nov 2025 | UNLISTED BUYER | Netherlands | Tablet | 1 | NOS | $1.26 | $1.26 | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 7 | Dec 2025 | UNLISTED BUYER | Netherlands | Tablet | 1 | NOS | $1.55 | $1.55 | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
8 countries · 31 shipments · $101K · 14 Indian suppliers · 10 buyers
SHIPMENTS
31
USD
$101K
COUNTRIES
8
SUPPLIERS
14
BUYERS
10
HHI
2,563
concentrated
Top 8 destination countries in Americas
1
Venezuela (61.2%)
$62K
2
Dominican Republic (13.4%)
$14K
3
Nicaragua (13.0%)
$13K
4
Guyana (7.1%)
$7K
5
Guatemala (2.7%)
$3K
6
Haiti (2.5%)
$2K
7
Dominica (0.0%)
$0.138
8
Bolivia (0.0%)
$0.0016
Top 14 Indian suppliers into Americas
1
LUCENT BIOTECH LTD
$45K
2
SAGA LIFESCIENCES LTD
$14K
3
INTERMED LABORATORIES PVT LTD
$13K
4
LARK LABORATORIES (INDIA) LTD
$11K
5
MARYUS HEALTHCARE PVT LTD
$5K
6
WEXFORD LABORATORIES PVT LTD
$4K
7
BALAXI PHARMACEUTICALS LTD
$3K
8
SYNCOM FORMULATIONS (INDIA) LTD
$2K
9
AASHIRWAD PHARMA INTERNATIONAL PVT LTD
$2K
10
CUMED LIFESCIENCES
$912.47
11
FENNY GLOBAL CARE PVT LTD
$140.83
12
PEAK HEALTHCARE
$32.86
13
SOINS IMPEX
$19.21
14
SEVATTO PHARMA
$0.0016
Top 9 Americas importers
1
UNIVERSAL MARKETING ASSOCIATES, S.A · Nicaragua
$13K
2
LABORATORIOS BUKA C.A · Venezuela
$11K
3
NEW GPC INC · Guyana
$5K
4
LABOPHARMACOS SRL · Dominican Republic
$4K
5
BALAXI HEALTHCARE GUATEMALA, S.A · Guatemala
$3K
6
BERYL PHARMA SRL · Dominican Republic
$912.47
7
POONAI BHIGROOG · Guyana
$45.87
8
DR BALWANT SINGHS HOSPITAL INC · Guyana
$19.21
9
FIRST CHOICE PHARMACY · Dominica
$0.138
Top 2 dosage forms
1
Tablet
$99K
2
Unknown
$2K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 6 | $14K | $2K |
| Nov | 6 | $12K | $2K |
| Dec | 19 | $75K | $4K |
Shipment register · 31 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — LUCENT BIOTECH LTD · 5 shipments · $45K | |||||||||||
| 1 | Dec 2025 | UNLISTED BUYER | Venezuela | Tablet | 29.2K | NOS | $0.311 | $9K | NHAVA SHEVA SEA (JNPT) | La Guaira | SEA |
| 2 | Dec 2025 | UNLISTED BUYER | Venezuela | Tablet | 29.2K | NOS | $0.311 | $9K | NHAVA SHEVA SEA (JNPT) | La Guaira | SEA |
| 3 | Dec 2025 | UNLISTED BUYER | Venezuela | Tablet | 29.2K | NOS | $0.311 | $9K | NHAVA SHEVA SEA (JNPT) | La Guaira | SEA |
| 4 | Dec 2025 | UNLISTED BUYER | Venezuela | Tablet | 29.2K | NOS | $0.311 | $9K | NHAVA SHEVA SEA (JNPT) | La Guaira | SEA |
| 5 | Dec 2025 | UNLISTED BUYER | Venezuela | Tablet | 29.2K | NOS | $0.310 | $9K | NHAVA SHEVA SEA (JNPT) | La Guaira | SEA |
| SUPPLIER #2 — SAGA LIFESCIENCES LTD · 4 shipments · $14K | |||||||||||
| 6 | Oct 2025 | UNLISTED BUYER | Venezuela | Tablet | 496 | NOS | $1.07 | $528.35 | AHMEDABAD ICD | La Guaira | ICD |
| 7 | Nov 2025 | UNLISTED BUYER | Venezuela | Tablet | 14.9K | NOS | $0.325 | $5K | AHMEDABAD ICD | LA GUAIRA | ICD |
| 8 | Dec 2025 | UNLISTED BUYER | Dominican Republic | Tablet | 3.0K | NOS | $1.67 | $5K | AHMEDABAD ICD | CAUCEDO DOMINIC REP. | ICD |
| 9 | Dec 2025 | UNLISTED BUYER | Dominican Republic | Tablet | 2.0K | NOS | $1.67 | $3K | AHMEDABAD ICD | CAUCEDO DOMINIC REP. | ICD |
| SUPPLIER #3 — INTERMED LABORATORIES PVT LTD · 2 shipments · $13K | |||||||||||
| 10 | Dec 2025 | UNIVERSAL MARKETING ASSOCIATES, S.A | Nicaragua | Tablet | 35.3K | NOS | $0.357 | $13K | CHENNAI SEA | Corinto | SEA |
| 11 | Dec 2025 | UNIVERSAL MARKETING ASSOCIATES, S.A | Nicaragua | Tablet | 140.2K | NOS | $0.0038 | $534.34 | CHENNAI SEA | Corinto | SEA |
| SUPPLIER #4 — LARK LABORATORIES (INDIA) LTD · 1 shipments · $11K | |||||||||||
| 12 | Oct 2025 | LABORATORIOS BUKA C.A | Venezuela | Tablet | 16.5K | NOS | $0.662 | $11K | DADRI ICD | LA GUAIRA | ICD |
| SUPPLIER #5 — MARYUS HEALTHCARE PVT LTD · 1 shipments · $5K | |||||||||||
| 13 | Dec 2025 | NEW GPC INC | Guyana | Tablet | 1.4K | NOS | $3.59 | $5K | MUMBAI AIR (SAHAR) | GEORGETOWN | AIR |
| SUPPLIER #6 — WEXFORD LABORATORIES PVT LTD · 2 shipments · $4K | |||||||||||
| 14 | Nov 2025 | LABOPHARMACOS SRL | Dominican Republic | Tablet | 9.5K | NOS | $0.081 | $769.02 | CHENNAI SEA | Santo Domingo | SEA |
| 15 | Nov 2025 | LABOPHARMACOS SRL | Dominican Republic | Tablet | 183.3K | NOS | $0.019 | $4K | CHENNAI SEA | Santo Domingo | SEA |
| SUPPLIER #7 — BALAXI PHARMACEUTICALS LTD · 2 shipments · $3K | |||||||||||
| 16 | Dec 2025 | BALAXI HEALTHCARE GUATEMALA, S.A | Guatemala | Tablet | 4.9K | TBS | $0.549 | $3K | NHAVA SHEVA SEA (JNPT) | Puerto Quetzal | SEA |
| 17 | Dec 2025 | BALAXI HEALTHCARE GUATEMALA, S.A | Guatemala | Tablet | 102 | TBS | $0.549 | $56.00 | NHAVA SHEVA SEA (JNPT) | Puerto Quetzal | SEA |
| SUPPLIER #8 — SYNCOM FORMULATIONS (INDIA) LTD · 3 shipments · $2K | |||||||||||
| 18 | Oct 2025 | UNLISTED BUYER | Haiti | Tablet | 57 | NOS | $42.41 | $2K | PITHAMPUR ICD | PORT-AU-PRINCE | ICD |
| 19 | Oct 2025 | UNLISTED BUYER | Haiti | Tablet | 1 | NOS | $33.93 | $33.93 | PITHAMPUR ICD | PORT-AU-PRINCE | ICD |
| 20 | Oct 2025 | UNLISTED BUYER | Haiti | Tablet | 1 | NOS | $29.69 | $29.69 | PITHAMPUR ICD | PORT-AU-PRINCE | ICD |
| SUPPLIER #9 — AASHIRWAD PHARMA INTERNATIONAL PVT LTD · 4 shipments · $2K | |||||||||||
| 21 | Nov 2025 | UNLISTED BUYER | Guyana | 1.0K | NOS | $0.519 | $519.11 | NHAVA SHEVA SEA (JNPT) | Georgetown | SEA | |
| 22 | Nov 2025 | UNLISTED BUYER | Guyana | 3.0K | NOS | $0.519 | $2K | NHAVA SHEVA SEA (JNPT) | Georgetown | SEA | |
| 23 | Dec 2025 | POONAI BHIGROOG | Guyana | Tablet | 200 | NOS | $0.229 | $45.87 | MUMBAI AIR (SAHAR) | GEORGETOWN | AIR |
| 24 | Dec 2025 | FIRST CHOICE PHARMACY | Dominica | Tablet | 150 | NOS | $0.0009 | $0.138 | MUMBAI AIR (SAHAR) | YEOSU | AIR |
| SUPPLIER #10 — CUMED LIFESCIENCES · 1 shipments · $912.47 | |||||||||||
| 25 | Nov 2025 | BERYL PHARMA SRL | Dominican Republic | Tablet | 2.6K | NOS | $0.344 | $912.47 | NHAVA SHEVA SEA (JNPT) | Rio Haina | SEA |
| SUPPLIER #11 — FENNY GLOBAL CARE PVT LTD · 1 shipments · $140.83 | |||||||||||
| 26 | Dec 2025 | UNLISTED BUYER | Guyana | Tablet | 200 | NOS | $0.704 | $140.83 | AHMEDABAD ICD | GEORGETOWN | ICD |
| SUPPLIER #12 — PEAK HEALTHCARE · 3 shipments · $32.86 | |||||||||||
| 27 | Dec 2025 | UNLISTED BUYER | Guyana | Tablet | 34 | NOS | $0.483 | $16.44 | NHAVA SHEVA SEA (JNPT) | Georgetown | SEA |
| 28 | Dec 2025 | UNLISTED BUYER | Guyana | Tablet | 34 | NOS | $0.0000 | $0.0000 | NHAVA SHEVA SEA (JNPT) | Georgetown | SEA |
| 29 | Dec 2025 | UNLISTED BUYER | Guyana | Tablet | 34 | NOS | $0.483 | $16.43 | NHAVA SHEVA SEA (JNPT) | Georgetown | SEA |
| SUPPLIER #13 — SOINS IMPEX · 1 shipments · $19.21 | |||||||||||
| 30 | Oct 2025 | DR BALWANT SINGHS HOSPITAL INC | Guyana | Tablet | 17 | NOS | $1.13 | $19.21 | AHMEDABAD AIR | GEORGETOWN | AIR |
| SUPPLIER #14 — SEVATTO PHARMA · 1 shipments · $0.0016 | |||||||||||
| 31 | Dec 2025 | UNLISTED BUYER | Bolivia | Tablet | 2 | NOS | $0.0008 | $0.0016 | MUMBAI AIR (SAHAR) | LAPAZ | AIR |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
1 countries · 1 shipments · $30.60 · 1 Indian suppliers · 1 buyers
SHIPMENTS
1
USD
$30.60
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Oceania
1
Nauru (100.0%)
$30.60
Top 1 Indian suppliers into Oceania
1
HLL LIFECARE LTD
$30.60
Top 1 Oceania importers
1
REPUBLIC OF NAURU - DEPARTMENT OF H · Nauru
$30.60
Top 1 dosage forms
1
Tablet
$30.60
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 0 | $0.0000 | — |
| Dec | 1 | $30.60 | $30.60 |
Shipment register · 1 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — HLL LIFECARE LTD · 1 shipments · $30.60 | |||||||||||
| 1 | Dec 2025 | REPUBLIC OF NAURU - DEPARTMENT OF H | Nauru | Tablet | 1.5K | NOS | $0.020 | $30.60 | DELHI AIR | NAURU ISLAND | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 35 Indian glibenclamide exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped glibenclamide in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | CIPLA LTD | PAREL MUMBAI MAHARASHTRA | 6 | $47K | Tablet | Africa |
| 2 | LUCENT BIOTECH LTD | ROORKEE | 5 | $45K | Tablet | Americas |
| 3 | ZYDUS LIFESCIENCES LTD | PONDA | 8 | $37K | Tablet | Africa, Asia |
| 4 | SHALINA LABORATORIES PVT LTD | MUMBAI | 14 | $20K | Tablet | Africa |
| 5 | MEDOPHARM | CHENNAI | 5 | $16K | Tablet | Asia, Europe |
| 6 | SAGA LIFESCIENCES LTD | TALUKA SANAND | 4 | $14K | Tablet | Americas |
| 7 | INTERMED LABORATORIES PVT LTD | CHENNAI | 2 | $13K | Tablet | Americas |
| 8 | LARK LABORATORIES (INDIA) LTD | NEW DELHI | 1 | $11K | Tablet | Americas |
| 9 | S KANT HEALTHCARE LTD | WORLI | 1 | $9K | Tablet | Asia |
| 10 | MEDICAMEN BIOTECH LTD | BHIWADI ALWAR | 1 | $6K | Tablet | Africa |
| 11 | MARYUS HEALTHCARE PVT LTD | MALAD | 1 | $5K | Tablet | Americas |
| 12 | AURA LIFECARE PVT LTD | KARACHIYA TAL SAVLI | 2 | $5K | Tablet | Africa |
| 13 | WEXFORD LABORATORIES PVT LTD | TUMKUR | 2 | $4K | Tablet | Americas |
| 14 | CIRON DRUGS AND PHARMACEUTICALS PVT LTD | MUMBAI | 1 | $3K | Tablet | Africa |
| 15 | BALAXI PHARMACEUTICALS LTD | JUBILEE HILLS HYDERABAD | 2 | $3K | Tablet | Americas |
| 16 | AGOG PHARMA LTD | VASAI EAST | 2 | $3K | Tablet | Africa |
| 17 | SYNCOM FORMULATIONS (INDIA) LTD | PITHAMPUR | 3 | $2K | Tablet | Americas |
| 18 | YUYU MEDIMPEX PVT LTD | MUMBAI | 2 | $2K | Tablet | Europe |
| 19 | CADILA PHARMACEUTICALS LTD | AHMEDABAD | 1 | $2K | Tablet | Europe |
| 20 | AASHIRWAD PHARMA INTERNATIONAL PVT LTD | PUNE | 4 | $2K | Tablet | Americas |
| 21 | SPEY MEDICAL PVT LTD | NEW DELHI | 1 | $1K | Tablet | Asia |
| 22 | CUMED LIFESCIENCES | DELHI | 1 | $912.47 | Tablet | Americas |
| 23 | ACCRESHA LIFECARE PVT LTD | AHMEDABAD | 1 | $738.60 | Tablet | Africa |
| 24 | LEBEN LABORATORIES PVT LTD | AKOLA. MAHARASHTRA | 1 | $546.53 | Tablet | Africa |
| 25 | MICRO LABS LTD | HOSUR | 1 | $233.07 | Tablet | Asia |
| 26 | REGAL LABORATORIES | TARN TARAN | 1 | $152.14 | Tablet | Africa |
| 27 | FENNY GLOBAL CARE PVT LTD | ANAND | 1 | $140.83 | Tablet | Americas |
| 28 | CURE EARTH PHARMA | Chennai | 3 | $106.91 | Tablet | Africa |
| 29 | PEAK HEALTHCARE | MUMBAI | 3 | $32.86 | Tablet | Americas |
| 30 | HLL LIFECARE LTD | UTTAR PRADESH | 1 | $30.60 | Tablet | Oceania |
| 31 | SOINS IMPEX | PHASE-1 | 1 | $19.21 | Tablet | Americas |
| 32 | NALIINI.R.EXPORT PVT LTD | CHENNAI | 1 | $15.85 | Tablet | Africa |
| 33 | RUCHA ENTERPRISES | MUMBAI | 3 | $2.82 | Tablet | Europe, Asia |
| 34 | MOVID IMPEX | MUMBAI | 2 | $2.72 | Tablet | Asia |
| 35 | SEVATTO PHARMA | Vadodara | 1 | $0.0016 | Tablet | Americas |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 36 global glibenclamide importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian glibenclamide in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | LABOREX | Madagascar | 4 | $39K | CIPLA LTD | Tablet |
| 2 | ABACUS PHARMA (A) LTD | Tanzania | 3 | $28K | ZYDUS LIFESCIENCES LTD | Tablet |
| 3 | SHALINA HEALTHCARE SARL | DR Congo | 6 | $18K | SHALINA LABORATORIES… | Tablet |
| 4 | UNIVERSAL MARKETING ASSOCIATES, S.A | Nicaragua | 2 | $13K | INTERMED LABORATORIE… | Tablet |
| 5 | LABORATORIOS BUKA C.A | Venezuela | 1 | $11K | LARK LABORATORIES (I… | Tablet |
| 6 | OPHAM | Madagascar | 2 | $8K | CIPLA LTD | Tablet |
| 7 | PLANET PHARMACEUTICALS CHEMICALS | Zimbabwe | 1 | $6K | MEDICAMEN BIOTECH LTD | Tablet |
| 8 | IMRES B.V | Netherlands | 1 | $5K | MEDOPHARM | Tablet |
| 9 | NEW GPC INC | Guyana | 1 | $5K | MARYUS HEALTHCARE PV… | Tablet |
| 10 | LABOPHARMACOS SRL | Dominican Republic | 2 | $4K | WEXFORD LABORATORIES… | Tablet |
| 11 | AL-JABAL DRUGS AND MEDICAL APPLIANC | Yemen | 1 | $4K | ZYDUS LIFESCIENCES LTD | Tablet |
| 12 | ABACUS PHARMA (AFRICA) LTD | Kenya | 3 | $3K | ZYDUS LIFESCIENCES LTD | Tablet |
| 13 | BALAXI HEALTHCARE GUATEMALA, S.A | Guatemala | 2 | $3K | BALAXI PHARMACEUTICA… | Tablet |
| 14 | GITTOES PHARMACEUTICALS LTD | Kenya | 1 | $3K | AGOG PHARMA LTD | Tablet |
| 15 | PHARMACEUTICAL WAREHOUSING INC | Netherlands Antilles | 2 | $2K | YUYU MEDIMPEX PVT LTD | Tablet |
| 16 | LUA COMERCIO GERAL LIMITADA | Angola | 1 | $2K | AURA LIFECARE PVT LTD | Tablet |
| 17 | MSF SUPPLY | Belgium | 1 | $2K | CADILA PHARMACEUTICA… | Tablet |
| 18 | NEW CESAMEX SARL | DR Congo | 1 | $2K | AURA LIFECARE PVT LTD | Tablet |
| 19 | IMPERIAL MEDICAL SOLUTIONS FZE | United Arab Emirates | 1 | $2K | MEDOPHARM | Tablet |
| 20 | U.N.R.W.A | Lebanon | 1 | $1K | MEDOPHARM | Tablet |
| 21 | DUSTI PHARMA LLC | Tajikistan | 1 | $1K | SPEY MEDICAL PVT LTD | Tablet |
| 22 | BERYL PHARMA SRL | Dominican Republic | 1 | $912.47 | CUMED LIFESCIENCES | Tablet |
| 23 | SALAMA(CENTRAL PURCHASING AGENCY | Madagascar | 1 | $738.60 | ACCRESHA LIFECARE PV… | Tablet |
| 24 | SHALINA PHARMACY LTD | South Sudan | 3 | $720.29 | SHALINA LABORATORIES… | Tablet |
| 25 | PHARMAVET LTD | Malawi | 1 | $546.53 | LEBEN LABORATORIES P… | Tablet |
| 26 | CENTRAL PHARMACEUTICAL JOINT STOCK | Vietnam | 1 | $233.07 | MICRO LABS LTD | Tablet |
| 27 | SONIA PHARMACY | Equatorial Guinea | 1 | $152.14 | REGAL LABORATORIES | Tablet |
| 28 | KALKAAL HOSPITAL | Somalia | 3 | $106.91 | CURE EARTH PHARMA | Tablet |
| 29 | POONAI BHIGROOG | Guyana | 1 | $45.87 | AASHIRWAD PHARMA INT… | Tablet |
| 30 | SUN ENTERPRISES LTD | Tanzania | 1 | $41.00 | AGOG PHARMA LTD | Tablet |
| 31 | REPUBLIC OF NAURU - DEPARTMENT OF H | Nauru | 1 | $30.60 | HLL LIFECARE LTD | Tablet |
| 32 | DR BALWANT SINGHS HOSPITAL INC | Guyana | 1 | $19.21 | SOINS IMPEX | Tablet |
| 33 | CENTRAL POINT PHARMACY | Seychelles | 1 | $15.85 | NALIINI.R.EXPORT PVT… | Tablet |
| 34 | AFRICA PHARMACY LIMITADA | Angola | 2 | $7.55 | SHALINA LABORATORIES… | Tablet |
| 35 | EMIRATES POST GROUP | United Arab Emirates | 2 | $2.72 | MOVID IMPEX | Tablet |
| 36 | FIRST CHOICE PHARMACY | Dominica | 1 | $0.138 | AASHIRWAD PHARMA INT… | Tablet |
This report covers 89 2025-Q4 Glibenclamide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/glibenclamide
Talk to our trade analyst
Need a custom glibenclamide report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/glibenclamide
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Glibenclamide product page
Live data, supplier directory, price trends, and trade route analysis